From what I heard in the interview, Rebecca's comment on scarcity of neurosurgeons was about the trials themselves, not the final product.
Given this scarcity, the trials become not only expensive but logistically challenging to plan and conduct.
Her feeling seems to be that CHM's limited resources are better focused on the other trials... at least for now.
- Forums
- ASX - By Stock
- Webinar 17/06/24
From what I heard in the interview, Rebecca's comment on...
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.52M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.8¢ | $17.55K | 951.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 2478600 | 1.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 1586922 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 2510883 | 0.018 |
7 | 1114148 | 0.017 |
17 | 4842828 | 0.016 |
7 | 1868566 | 0.015 |
3 | 2121000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 115949 | 3 |
0.020 | 1586922 | 4 |
0.021 | 1023435 | 6 |
0.022 | 300000 | 2 |
0.023 | 335000 | 3 |
Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Chairman
Nick Poll
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online